Physician profile
Ramez Andrawis
NPI 1326192360
$3,770.24
in general payments reported to CMS, 2019-2025
30 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $197 · 2021: $409 · 2022: $613 · 2023: $521 · 2024: $548 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $777.53 | 2019-2024 | Xtandi, Myrbetriq |
| Dornier Medtech America, INC | $389.62 | 2023 | Dornier Medtech |
| Sumitomo Pharma America, INC. | $359.74 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $295.61 | 2019-2025 | Erleada |
| Pfizer INC. | $233.46 | 2019-2025 | |
| Urovant Sciences INC | $180.01 | 2022 | |
| Ferring Pharmaceuticals INC. | $170.79 | 2019-2025 | Adstiladrin |
| Urogen Pharma, INC. | $147.26 | 2021-2025 | |
| Neotract INC. | $137.34 | 2019 | |
| Agiliti Surgical, INC. | $102.48 | 2025 | Sonablate Hifu |
| Dendreon Pharmaceuticals LLC | $94.90 | 2019-2020 | |
| Ethicon US, LLC | $85.50 | 2019 | |
| Myovant Sciences INC. | $77.61 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $74.15 | 2019-2024 | Xiaflex |
| Tolmar Pharmaceuticals, INC. | $72.97 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $69.51 | 2020-2025 | Spaceoar Vue System - 10ml, Lithovue |
| Olympus America INC. | $69.26 | 2019-2023 | Itind System |
| Procept Biorobotics Corporation | $60.00 | 2025 | |
| Allergan, INC. | $50.90 | 2019-2020 | |
| Axonics, INC. | $48.38 | 2022-2023 | Axonics |
| Endo USA, INC. | $42.06 | 2024-2025 | Xiaflex |
| Amgen INC. | $35.45 | 2019 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Genzyme Corporation | $27.51 | 2022 | |
| Tolmar, INC. | $24.85 | 2024 | |
| Becton, Dickinson and Company | $23.86 | 2019 | |
| Antares Pharma, INC. | $23.82 | 2024 | Xyosted |
| Laborie Medical Technologies Corp. | $23.04 | 2025 | |
| Abbvie INC. | $21.29 | 2025 | |
| Palette Life Sciences, INC. | $20.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramez Andrawis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.